[Therapeutic protocol corresponding position No. 116 code (LB01B)]

2015 Official Gazette of Romania No. 275/162, Annex 14 (10/03/2015)

"Therapeutic protocol and cirrhosis in chronic HBV Hepatitis is amended to read as follows: Diagnosis, eligibility criteria, regimens and follow choice during antiviral therapy of patients with chronic HBV liver cirrhosis
CHRONIC HEPATITIS HBV
- NAÏVE PATIENTS Criteria for inclusion in treatment Evaluation of fibrosis and necro-inflammatory activity will be done by Fibromax, Fibro-ActiTest, Fibroscan or PBH, all patients with normal ALT and HBV viral load> 2,000 IU / ml at the initiation of antiviral medication. If histological evaluation showing at least F1 or A1 patients are candidates for antiviral medication (therefore any of the F1A0, F1A1, F0A1 or more is an indication of antiviral therapy in HBV DNA> 2000 IU / ml). If it is necessary to use Fibroscan a value of at least 7 kPa.
COMPENSATED LIVER CIRRHOSIS
Criteria for inclusion in treatment
- Detectable viral load, regardless of value
- IgG anti-HDV negative;
- Histologically proven cirrhosis (PBH, Fibromax or Fibroscan)
COINFECTION HBV + HDV
- NAÏVE PATIENTS Therapy in case viral load detectable HBV and HDV viral load regardless of value Criteria for inclusion in treatment Evaluation of fibrosis and necro-inflammatory activity will be done by Fibromax, Fibro-ActiTest or PBH, all patients with normal ALT, HBV viral load detectable viral load VHD regardless of value. If histologic evaluation looks at least F1 or A1 patients are eligible for antiviral medication (therefore any F1A0 situations, F1A1, F0A1 or more antiviral therapy is indication viremia> 2000 IU / ml). It also accepts Fibroscan to a value of over 7kPa.
CHRONIC HEPATITIS HBV
- PEDIATRIC PATIENTS
- NAÏVE PATIENTS Criteria for inclusion in treatment Evaluation of fibrosis and necro-inflammatory activity will be done by Fibromax, Fibro-ActiTest or PBH, all patients at initiation of antiviral medication. Regardless of the degree of fibrosis or necroinflammatory grade, patients with chronic hepatitis HBV viral load> 2000 / ml, are eligible for antiviral medication. We do not accept Fibroscan considering the fact that it cannot assess the work necroinflammatory.
COINFECTION HBV + HDV
- PEDIATRIC PATIENTS
- NAÏVE PATIENTS Criteria for inclusion in treatment Evaluation of fibrosis and necro-inflammatory activity will be done by Fibromax, Fibro-ActiTest or PBH, all patients with normal ALT, HBV viral load> 2000 IU / ml and / or HDV viral load positive regardless of value. If histologic evaluation looks at least F1 or A1 patients are eligible for antiviral medication (therefore any F1A0 situations, F1A1, F0A1 or more antiviral therapy is indication viral load> 2000 IU / ml). It also accepts Fibroscan to a value of over 7kPa."